Answers are grounded in this paper and cite their sources.
Great advances have been made in the treatment of Tay–Sachs disease, one of a group of inherited diseases in which the degradation of sphingolipids is impaired. In the animal model, application of compound 1 was successful in inhibiting the biosynthesis of nondegradable enzyme substrates and in this way reducing the extent of the disease.
No takes yet. Share an insight, caveat, or question.
Thomas Kolter (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: